orthomolecular l-carnitine 500 mg Supplement ALCAR-N-Acetyl-L-Carnitine

Another small clinical trial amongst 16 HIVpositive patients evaluated IM and IV ALC with a dose of 500-1000 mg/d over 3 weeks and found that the treatment improved symptoms in 62.5% of patients

Int J Pharm X

Its stable organic-acid complex offers superior absorption and functional bioavailability, enabling manufacturers to formulate targeted solutions for anemia support, fatigue reduction, womens health, and performance nutrition

Even though there are concerns for the development of kidney disease in CPTII patients due to the high metabolic overload associated to rhabdomyolysis, end-stage chronic renal insufficiency requiring dialysis is only occasionally reported in these patients (Joshi and Zierz, 2020)

10.1111/j.17433150.2004.00490.x 44